Side-by-side comparison of AI visibility scores, market position, and capabilities
Seattle AI drug discovery targeting transcription factors with MARMOT platform measuring 10,000 regulomes monthly; YC W21 $11.2M with FDA/EMA Phase I approval for MSD-001 cancer program.
Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.